Earlier this year, a promising antibiotic named teixobactin with the ability to vanquish drug-resistant pathogen was discovered. Early results show teixobactin to be active against the deadly bacterium MRSA (methicillin-resistant Staphylococcus aureus) in mice. This important discovery was made possible by the work Slava Epstein and his lab, who developed the iCHIP technology. Story originally posted by Nature. Follow this link to view the original story >
The iCHIP technology has the potential to change antibiotic development by opening a whole new research alternative – high throughput development – to the field. In October this year, Slava is joining us at the inaugural World Anti-Microbial Resistance Congress to discuss not only his new technology, but some novel work that his lab has been doing to push the field forward.
Join him to hear the latest on:
- Solving the great plate count anomaly by bringing the microbial environment to the lab
- Utilizing a diffusion chamber to capture microbial growth while allowing nutrient exchange
- Thousands of newly cultivated microbes allowing for increased efficiency of novel antibiotic discovery and development
To book, simply visit the website >